Information for consumers
SUBOXONE (also known as buprenorphine and naloxone) will be available in 2 dosage forms: a soluble film (placed under the tongue or inside the cheek) and a sublingual tablet (placed under the tongue). Both dosage forms are used as part of a medical, social and psychological treatment program for adults undergoing substitution treatment for problematic opioid drug dependence.
Switching between SUBOXONE film and tablet, or switching the location of where the film is placed inside the mouth, may affect how much medicine is absorbed into the body. Patients should not switch between the tablet and the film unless directed by their doctor. Patients should not change their treatment in any way, or stop their treatment, without first consulting their doctor. Doctors may change the dose of SUBOXONE after seeing how it affects patients.
When beginning treatment with SUBOXONE film, patients should only take it under the tongue. After a few days, patients can choose (after consulting their doctor) whether they will take the film under the tongue or on the inside of their cheek.
Patients should monitor for any signs and symptoms of overdose or underdose when changes to their treatment are made.
Signs of overdose may include unusually slow or weak breathing, dizziness, confusion or extreme drowsiness.
Signs of underdose include withdrawal symptoms such as body aches, diarrhea, goosebumps, loss of appetite, nausea, feeling nervous or restless, runny nose, sneezing, tremors or shivering, stomach cramps, rapid heart rate, trouble sleeping, an unusual increase in sweating, heart palpitations, an unexplained fever, weakness or yawning.
Patients should discuss any questions or concerns about this information with their healthcare professional.
Information for healthcare professionals
Healthcare professionals should be aware of the following when switching patients between SUBOXONE Soluble Film and SUBOXONE Sublingual Tablet:
-
Patients being switched between the tablet and the film should be started on the same dosage of the previously administered product. When switching between the tablet and film, patients should be monitored in case there is a need to adjust the dose.
-
When switching from tablet to film, the film should initially be administered sublingually. Patients who are stabilized on sublingually-administered film can be switched to buccally-administered film.
-
Due to the greater bioavailability of the film compared to the tablet at certain strengths, patients switching from tablet to film should be monitored for symptoms of overdose. Those switching from film to tablet should be monitored for symptoms of underdose, including opioid withdrawal.
-
Combining or alternating between film and tablet dosage forms is not advised.
Healthcare professionals should be aware of the following when switching patients between sublingual and buccal sites of administration with SUBOXONE Soluble Film:
-
For induction, the film should only be administered sublingually.
-
Once induction with the film is complete (typically within 2 days), patients can be switched between sublingual to buccal administration without significant risk of overdosing or underdosing. This is because the systemic exposure of buprenorphine between buccal and sublingual administration of the film is similar.
-
Patients should be monitored when switching between the two routes of administration.
Action taken by Health Canada
The Canadian Product Monograph (CPM) for SUBOXONE contains the recommendations outlined in this communication. The SUBOXONE CPM can be found on
Health Canada’s Drug Product Database.
Health Canada is communicating this important safety information to healthcare professionals and Canadians via the
Recalls and Safety Alerts Database on the Healthy Canadians Web Site. This communication will be further distributed through the MedEffect™ e-Notice email notification system as well as through social media channels, including LinkedIn and Twitter.